Cas:1012059-96-9 benzyl N-[(2R)-4-(methylamino)-4-oxo-1-phenylsulfanylbutan-2-yl]carbamate manufacturer & supplier

Chemical Name:benzyl N-[(2R)-4-(methylamino)-4-oxo-1-phenylsulfanylbutan-2-yl]carbamate

CAS.NO:1012059-96-9

Synonyms:benzyl N-[(2R)-4-(methylamino)-4-oxo-1-phenylsulfanylbutan-2-yl]carbamate

Molecular Formula:C₁₉H₂₂N₂O₃S

Molecular Weight:358.45500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:99.71000

Exact Mass:358.13500

LogP:4.25450

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like benzyl N-[(2R)-4-(methylamino)-4-oxo-1-phenylsulfanylbutan-2-yl]carbamate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,benzyl N-[(2R)-4-(methylamino)-4-oxo-1-phenylsulfanylbutan-2-yl]carbamate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,benzyl N-[(2R)-4-(methylamino)-4-oxo-1-phenylsulfanylbutan-2-yl]carbamate Use and application,benzyl N-[(2R)-4-(methylamino)-4-oxo-1-phenylsulfanylbutan-2-yl]carbamate technical grade,usp/ep/jp grade.

Related News: Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application. benzyl N-[(2R)-4-(methylamino)-4-oxo-1-phenylsulfanylbutan-2-yl]carbamate manufacturer Lilly has pledged to address the problems, and said none of them affected drugs in the market. The FDA, which has taken no public action, did not respond to requests for comment. benzyl N-[(2R)-4-(methylamino)-4-oxo-1-phenylsulfanylbutan-2-yl]carbamate supplier With the continuous accumulation of the API industry and the increasing maturity of the market, competition in China’s API industry will become increasingly fierce. benzyl N-[(2R)-4-(methylamino)-4-oxo-1-phenylsulfanylbutan-2-yl]carbamate vendor Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. benzyl N-[(2R)-4-(methylamino)-4-oxo-1-phenylsulfanylbutan-2-yl]carbamate factory Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.